View ValuationKuros Biosciences 향후 성장Future 기준 점검 6/6Kuros Biosciences (는) 각각 연간 61.9% 및 23.9% 수익과 수익이 증가할 것으로 예상됩니다. EPS는 연간 62.8% 만큼 성장할 것으로 예상됩니다. 자기자본이익률은 3년 후 20.4% 로 예상됩니다.핵심 정보61.9%이익 성장률62.78%EPS 성장률Biotechs 이익 성장25.1%매출 성장률23.9%향후 자기자본이익률20.38%애널리스트 커버리지Low마지막 업데이트01 Jun 2026최근 향후 성장 업데이트공시 • Mar 10Kuros Biosciences AG Provides Earnings Guidance for the Year 2026-2028Kuros Biosciences AG provided earnings guidance for the year 2026-2028. For the year, the Group expects at least 35% sales growth. By 2028, the Group anticipates sales of USD 300 million to USD 330 million.공시 • Oct 16Kuros Biosciences AG Raises earnings Guidance for the Year 2025Kuros Biosciences AG raised earnings guidance for the year 2025. For the year, Group is raising its sales guidance and now expects growth of at least 70% .공시 • Aug 14Kuros Biosciences Ag Provides Earnings Guidance for the Year 2025 and by 2027Kuros Biosciences AG provided earnings guidance for the year 2025 and by 2027. For the year, the company expects robust sales growth of at least 60% in 2025. Kuros is anticipating sales of USD 220 to 250 million by 2027, reflecting its commitment to long-term value creation through innovation, market share gains, and customer satisfaction.공시 • Oct 10Kuros Biosciences AG Provides Sales Guidance for the Second Half of 2024Kuros Biosciences AG provided sales guidance for the second half of 2024. For the remainder of the second half of 2024, Kuros expects a similar seasonal sales pattern as in previous years, corresponding to around 57% to 60% of total annual sales.모든 업데이트 보기Recent updates공시 • Mar 26Kuros Biosciences AG, Annual General Meeting, Apr 15, 2026Kuros Biosciences AG, Annual General Meeting, Apr 15, 2026, at 11:00 W. Europe Standard Time.공시 • Mar 10Kuros Biosciences AG Provides Earnings Guidance for the Year 2026-2028Kuros Biosciences AG provided earnings guidance for the year 2026-2028. For the year, the Group expects at least 35% sales growth. By 2028, the Group anticipates sales of USD 300 million to USD 330 million.공시 • Oct 16Kuros Biosciences AG Raises earnings Guidance for the Year 2025Kuros Biosciences AG raised earnings guidance for the year 2025. For the year, Group is raising its sales guidance and now expects growth of at least 70% .공시 • Sep 04Kuros Biosciences Announces Board and Committee ChangesKuros Biosciences announced that Albert Arp has decided to resign from the Board of Directors with immediate effect for personal and professional reasons. Oliver Walker was appointed as Chair of the Audit and Risk Committee. Kimberley Elting was appointed as member of the Audit and Risk Committee and as member and Chair of the Compensation and Nomination Committee.공시 • Aug 16+ 1 more updateKuros Biosciences AG to Report Fiscal Year 2025 Results on Mar 10, 2026Kuros Biosciences AG announced that they will report fiscal year 2025 results on Mar 10, 2026공시 • Aug 14Kuros Biosciences Ag Provides Earnings Guidance for the Year 2025 and by 2027Kuros Biosciences AG provided earnings guidance for the year 2025 and by 2027. For the year, the company expects robust sales growth of at least 60% in 2025. Kuros is anticipating sales of USD 220 to 250 million by 2027, reflecting its commitment to long-term value creation through innovation, market share gains, and customer satisfaction.공시 • Aug 05Kuros Biosciences Launches Magnetos MIS Delivery System by Completion of the First U.S. Cases Using the New Magnetos MIS Delivery SystemKuros Biosciences announced the completion of the first U.S. cases using the new MagnetOsTM MIS Delivery System - a sterile, prefilled, single-use delivery system engineered for Minimally invasive Surgery in spine procedures. Following FDA 510(k) clearance of the MagnetOs MIS Delivery System in May, these first cases mark a significant milestone in expanding surgeon access to a more streamlined approach for graft delivery. Dr. Daniel Park, orthopedic spine surgeon, performed his first case using the new FDA-cleared system in Southfield, Michigan. MagnetOs MIS builds on the proven science of MagnetOs and its proprietary NeedleGrip submicron surface technology, which harnesses the immune system to stimulate bone growth. It is engineered for precise delivery, surgical efficiency, and predictable fusion outcomes. Compared to delivering MagnetOs in a traditional, funnel-based system, MagnetOs MIS achieved graft placement three times faster, optimizing time in the operating room. The MIS system is supported by robust published clinical evidence for MagnetOs in cases where minimally invasive procedures and surgical site accessibility is crucial. In a retrospective study, MagnetOs achieved a 94.4% fusion rate across 36 levels treated in patients undergoing MIS and open transforaminal lumbar interbody fusions, where the majority of patients had comorbidities such as obesity, smoking, diabetes, or a previous spine surgery. These results build on previously published Level I prospective, randomized, controlled human clinical data demonstrating that MagnetOs achieved nearly twice the fusion rate of autograft in posterolateral fusion (79% vs. 47%). Additionally, and following the recent ANVISA approval of MagnetOs Granules, Kuros also announced that MagnetOs Putty now has been approved by the Brazilian regulatory authority, expanding the company's entry into the South American spine and orthopedic market.공시 • Apr 15Kuros Biosciences Ag Elects Kimberley Elting as A New Member of the Board of DirectorsKuros Biosciences AG announced Kimberley Elting was elected as a new member of the Board of Directors.공시 • Mar 26Kuros Biosciences AG, Annual General Meeting, Apr 15, 2025Kuros Biosciences AG, Annual General Meeting, Apr 15, 2025, at 11:00 W. Europe Standard Time.공시 • Feb 25+ 1 more updateKuros Biosciences AG to Report Fiscal Year 2024 Results on Mar 11, 2025Kuros Biosciences AG announced that they will report fiscal year 2024 results on Mar 11, 2025공시 • Oct 10Kuros Biosciences AG Provides Sales Guidance for the Second Half of 2024Kuros Biosciences AG provided sales guidance for the second half of 2024. For the remainder of the second half of 2024, Kuros expects a similar seasonal sales pattern as in previous years, corresponding to around 57% to 60% of total annual sales.공시 • Apr 17Kuros Biosciences AG Approves Board of Director and Committee ChangesKuros Biosciences AG at the Annual general meeting approved Board of director and committee changes. Albert Arp and Chris Fair (CEO) were elected as new members of the Board of Directors, Albert Arp was elected as a new member of the Compensation Committee. Scott Bruder did not stand for re-election as member of the board.공시 • Mar 08Kuros Biosciences AG to Report Fiscal Year 2023 Results on Mar 13, 2024Kuros Biosciences AG announced that they will report fiscal year 2023 results on Mar 13, 2024공시 • Jan 31Kuros Biosciences Receives US FDA 510K Clearance for Magnetos Granules for Interbody Use and Regulatory Clearance of Magnetos Granules and Magnetos Putty in New ZealandKuros Biosciences announced clearance of a 510(k) submission from the U.S. Food and Drug Administration related to its MagnetOs Granules. The Company also announced clearance to market in New Zealand for MagnetOs Granules and MagnetOs Putty. The products are now commercially available through Vortek Spine Limited ("Vortek"), a high-tech orthopedic and biologics company specializing in healthcare solutions for surgeons and patients. This further expands the MagnetOs portfolio in terms of application and accessibility. Earlier in January, Kuros announced the FDA clearance of MagnetOs Easypack Putty for interbody use and MagnetOs Putty for standalone use in the posterolateral spine, meaning it can now be used without the need for autograft (patient's own bone). The availability of MagnetOs in New Zealand marks a significant milestone for Kuros and the local medical community since patients can now benefit from an advanced bone graft that improves the overall quality of care in orthopedic and spinal procedures. This benefit was further demonstrated with recent level 1 clinical data in which MagnetOs outperformed the gold standard autograft by 73% in posterior spinal fusion in a difficult-to-treat real life patient population, of which 20% were current smokers.공시 • Nov 29Kuros Biosciences Receives FDA Clearance for Use of Magnetos in Interbody Spinal CagesKuros Biosciences announced that MagnetOs Flex Matrix has been cleared for use in the interbody space by the U.S. Food and Drug Administration (FDA). As a result, it can now be used in any interbody space (cervical, thoracic, lumbar); and in any cage approved for use with a bone void filler. With interbody cages being used in almost half of the estimated 1.5 million instrumented spinal fusion procedures conducted annually in the USA, this news is especially significant for surgeons. MagnetOs Flex Matrix is uniquely well suited to interbody applications. Due to its excellent granule retention, it stays strong yet flexible even when wet - for easy placement either through a funnel or packed directly into any cage, of any size. MagnetOs Flex Matrix is the first Kuros product to receive interbody clearance, having already been cleared by the FDA for use in posterolateral fusions. Due to its unique fibrillar and flexible structure, this open matrix bone graft promotes bone growth even in soft tissue by optimizing the effect of Kuros' established NeedleGrip surface technology.이익 및 매출 성장 예측OTCPK:CSBT.F - 애널리스트 향후 추정치 및 과거 재무 데이터 (USD Millions)날짜매출이익자유현금흐름영업현금흐름평균 애널리스트 수12/31/2028310427379112/31/2027285295560212/31/2026200133038112/31/20251462-30N/A9/30/2025130-2-20N/A6/30/2025123-702N/A3/31/202599-512N/A12/31/202485-424N/A6/30/202459-6-4-3N/A3/31/202448-8-7-6N/A12/31/202340-12-11-11N/A9/30/202329-16-9-9N/A6/30/202323-18-9-8N/A3/31/202321-17-8-8N/A12/31/202219-16-8-8N/A9/30/202217-13-10-10N/A6/30/202216-12-12-12N/A3/31/202216-10-9-9N/A12/31/202115-8-6-6N/A9/30/202114-7-6-5N/A6/30/202113-6-5-5N/A3/31/20218-9-8-7N/A12/31/20205-13-11-10N/A9/30/20204-13-11-10N/A6/30/20203-13-11-10N/A3/31/20203-12-11-11N/A12/31/20193-12-11-11N/A9/30/20192-11N/A-12N/A6/30/20191-12N/A-13N/A3/31/20191-12N/A-13N/A12/31/20181-12N/A-13N/A9/30/20181-13N/A-13N/A6/30/20180-15N/A-12N/A3/31/20180-16N/A-12N/A12/31/20171-17N/A-11N/A9/30/20171-15N/A-11N/A6/30/20171-14N/A-11N/A3/31/20171-17N/A-10N/A12/31/20161-19N/A-9N/A9/30/20161-19N/A-7N/A6/30/20161-18N/A-6N/A3/31/20161-12N/A-4N/A12/31/20150-6N/A-3N/A더 보기애널리스트 향후 성장 전망수입 대 저축률: CSBT.F 의 연간 예상 수익 증가율(61.9%)이 saving rate(3.5%)보다 높습니다.수익 vs 시장: CSBT.F 의 연간 수익(61.9%)이 US 시장(18.4%)보다 빠르게 성장할 것으로 예상됩니다.고성장 수익: CSBT.F 의 수입은 향후 3년 동안 상당히 증가할 것으로 예상됩니다.수익 대 시장: CSBT.F 의 수익(연간 23.9%)이 US 시장(연간 12.7%)보다 빠르게 성장할 것으로 예상됩니다.고성장 매출: CSBT.F 의 수익(연간 23.9%)은 연간 20%보다 빠르게 증가할 것으로 예상됩니다.주당순이익 성장 예측향후 자기자본이익률미래 ROE: CSBT.F의 자본 수익률은 3년 후 20.4%로 높을 것으로 예상됩니다.성장 기업 찾아보기7D1Y7D1Y7D1YPharmaceuticals-biotech 산업의 고성장 기업.View Past Performance기업 분석 및 재무 데이터 상태데이터최종 업데이트 (UTC 시간)기업 분석2026/07/06 08:18종가2026/07/06 00:00수익2025/12/31연간 수익2025/12/31데이터 소스당사의 기업 분석에 사용되는 데이터는 S&P Global Market Intelligence LLC에서 제공됩니다. 아래 데이터는 이 보고서를 생성하기 위해 분석 모델에서 사용됩니다. 데이터는 정규화되므로 소스가 제공된 후 지연이 발생할 수 있습니다.패키지데이터기간미국 소스 예시 *기업 재무제표10년손익계산서현금흐름표대차대조표SEC 양식 10-KSEC 양식 10-Q분석가 컨센서스 추정치+3년재무 예측분석가 목표주가분석가 리서치 보고서Blue Matrix시장 가격30년주가배당, 분할 및 기타 조치ICE 시장 데이터SEC 양식 S-1지분 구조10년주요 주주내부자 거래SEC 양식 4SEC 양식 13D경영진10년리더십 팀이사회SEC 양식 10-KSEC 양식 DEF 14A주요 개발10년회사 공시SEC 양식 8-K* 미국 증권에 대한 예시이며, 비(非)미국 증권에는 해당 국가의 규제 서식 및 자료원을 사용합니다.별도로 명시되지 않는 한 모든 재무 데이터는 연간 기간을 기준으로 하지만 분기별로 업데이트됩니다. 이를 TTM(최근 12개월) 또는 LTM(지난 12개월) 데이터라고 합니다. 자세히 알아보기.분석 모델 및 스노우플레이크이 보고서를 생성하는 데 사용된 분석 모델에 대한 세부 정보는 당사의 Github 페이지에서 확인하실 수 있으며, 보고서 활용 방법에 대한 가이드와 YouTube 튜토리얼도 제공하고 있습니다.Simply Wall St 분석 모델을 설계하고 구축한 세계적 수준의 팀에 대해 알아보세요.산업 및 섹터 지표산업 및 섹터 지표는 Simply Wall St가 6시간마다 계산하며, 프로세스에 대한 자세한 내용은 Github에서 확인할 수 있습니다.분석가 소스Kuros Biosciences AG는 2명의 분석가가 다루고 있습니다. 이 중 2명의 분석가가 우리 보고서에 입력 데이터로 사용되는 매출 또는 수익 추정치를 제출했습니다. 분석가의 제출 자료는 하루 종일 업데이트됩니다.분석가기관Volker BosseBaader Helvea Equity ResearchThomas MeyerBaader Helvea Equity Research
공시 • Mar 10Kuros Biosciences AG Provides Earnings Guidance for the Year 2026-2028Kuros Biosciences AG provided earnings guidance for the year 2026-2028. For the year, the Group expects at least 35% sales growth. By 2028, the Group anticipates sales of USD 300 million to USD 330 million.
공시 • Oct 16Kuros Biosciences AG Raises earnings Guidance for the Year 2025Kuros Biosciences AG raised earnings guidance for the year 2025. For the year, Group is raising its sales guidance and now expects growth of at least 70% .
공시 • Aug 14Kuros Biosciences Ag Provides Earnings Guidance for the Year 2025 and by 2027Kuros Biosciences AG provided earnings guidance for the year 2025 and by 2027. For the year, the company expects robust sales growth of at least 60% in 2025. Kuros is anticipating sales of USD 220 to 250 million by 2027, reflecting its commitment to long-term value creation through innovation, market share gains, and customer satisfaction.
공시 • Oct 10Kuros Biosciences AG Provides Sales Guidance for the Second Half of 2024Kuros Biosciences AG provided sales guidance for the second half of 2024. For the remainder of the second half of 2024, Kuros expects a similar seasonal sales pattern as in previous years, corresponding to around 57% to 60% of total annual sales.
공시 • Mar 26Kuros Biosciences AG, Annual General Meeting, Apr 15, 2026Kuros Biosciences AG, Annual General Meeting, Apr 15, 2026, at 11:00 W. Europe Standard Time.
공시 • Mar 10Kuros Biosciences AG Provides Earnings Guidance for the Year 2026-2028Kuros Biosciences AG provided earnings guidance for the year 2026-2028. For the year, the Group expects at least 35% sales growth. By 2028, the Group anticipates sales of USD 300 million to USD 330 million.
공시 • Oct 16Kuros Biosciences AG Raises earnings Guidance for the Year 2025Kuros Biosciences AG raised earnings guidance for the year 2025. For the year, Group is raising its sales guidance and now expects growth of at least 70% .
공시 • Sep 04Kuros Biosciences Announces Board and Committee ChangesKuros Biosciences announced that Albert Arp has decided to resign from the Board of Directors with immediate effect for personal and professional reasons. Oliver Walker was appointed as Chair of the Audit and Risk Committee. Kimberley Elting was appointed as member of the Audit and Risk Committee and as member and Chair of the Compensation and Nomination Committee.
공시 • Aug 16+ 1 more updateKuros Biosciences AG to Report Fiscal Year 2025 Results on Mar 10, 2026Kuros Biosciences AG announced that they will report fiscal year 2025 results on Mar 10, 2026
공시 • Aug 14Kuros Biosciences Ag Provides Earnings Guidance for the Year 2025 and by 2027Kuros Biosciences AG provided earnings guidance for the year 2025 and by 2027. For the year, the company expects robust sales growth of at least 60% in 2025. Kuros is anticipating sales of USD 220 to 250 million by 2027, reflecting its commitment to long-term value creation through innovation, market share gains, and customer satisfaction.
공시 • Aug 05Kuros Biosciences Launches Magnetos MIS Delivery System by Completion of the First U.S. Cases Using the New Magnetos MIS Delivery SystemKuros Biosciences announced the completion of the first U.S. cases using the new MagnetOsTM MIS Delivery System - a sterile, prefilled, single-use delivery system engineered for Minimally invasive Surgery in spine procedures. Following FDA 510(k) clearance of the MagnetOs MIS Delivery System in May, these first cases mark a significant milestone in expanding surgeon access to a more streamlined approach for graft delivery. Dr. Daniel Park, orthopedic spine surgeon, performed his first case using the new FDA-cleared system in Southfield, Michigan. MagnetOs MIS builds on the proven science of MagnetOs and its proprietary NeedleGrip submicron surface technology, which harnesses the immune system to stimulate bone growth. It is engineered for precise delivery, surgical efficiency, and predictable fusion outcomes. Compared to delivering MagnetOs in a traditional, funnel-based system, MagnetOs MIS achieved graft placement three times faster, optimizing time in the operating room. The MIS system is supported by robust published clinical evidence for MagnetOs in cases where minimally invasive procedures and surgical site accessibility is crucial. In a retrospective study, MagnetOs achieved a 94.4% fusion rate across 36 levels treated in patients undergoing MIS and open transforaminal lumbar interbody fusions, where the majority of patients had comorbidities such as obesity, smoking, diabetes, or a previous spine surgery. These results build on previously published Level I prospective, randomized, controlled human clinical data demonstrating that MagnetOs achieved nearly twice the fusion rate of autograft in posterolateral fusion (79% vs. 47%). Additionally, and following the recent ANVISA approval of MagnetOs Granules, Kuros also announced that MagnetOs Putty now has been approved by the Brazilian regulatory authority, expanding the company's entry into the South American spine and orthopedic market.
공시 • Apr 15Kuros Biosciences Ag Elects Kimberley Elting as A New Member of the Board of DirectorsKuros Biosciences AG announced Kimberley Elting was elected as a new member of the Board of Directors.
공시 • Mar 26Kuros Biosciences AG, Annual General Meeting, Apr 15, 2025Kuros Biosciences AG, Annual General Meeting, Apr 15, 2025, at 11:00 W. Europe Standard Time.
공시 • Feb 25+ 1 more updateKuros Biosciences AG to Report Fiscal Year 2024 Results on Mar 11, 2025Kuros Biosciences AG announced that they will report fiscal year 2024 results on Mar 11, 2025
공시 • Oct 10Kuros Biosciences AG Provides Sales Guidance for the Second Half of 2024Kuros Biosciences AG provided sales guidance for the second half of 2024. For the remainder of the second half of 2024, Kuros expects a similar seasonal sales pattern as in previous years, corresponding to around 57% to 60% of total annual sales.
공시 • Apr 17Kuros Biosciences AG Approves Board of Director and Committee ChangesKuros Biosciences AG at the Annual general meeting approved Board of director and committee changes. Albert Arp and Chris Fair (CEO) were elected as new members of the Board of Directors, Albert Arp was elected as a new member of the Compensation Committee. Scott Bruder did not stand for re-election as member of the board.
공시 • Mar 08Kuros Biosciences AG to Report Fiscal Year 2023 Results on Mar 13, 2024Kuros Biosciences AG announced that they will report fiscal year 2023 results on Mar 13, 2024
공시 • Jan 31Kuros Biosciences Receives US FDA 510K Clearance for Magnetos Granules for Interbody Use and Regulatory Clearance of Magnetos Granules and Magnetos Putty in New ZealandKuros Biosciences announced clearance of a 510(k) submission from the U.S. Food and Drug Administration related to its MagnetOs Granules. The Company also announced clearance to market in New Zealand for MagnetOs Granules and MagnetOs Putty. The products are now commercially available through Vortek Spine Limited ("Vortek"), a high-tech orthopedic and biologics company specializing in healthcare solutions for surgeons and patients. This further expands the MagnetOs portfolio in terms of application and accessibility. Earlier in January, Kuros announced the FDA clearance of MagnetOs Easypack Putty for interbody use and MagnetOs Putty for standalone use in the posterolateral spine, meaning it can now be used without the need for autograft (patient's own bone). The availability of MagnetOs in New Zealand marks a significant milestone for Kuros and the local medical community since patients can now benefit from an advanced bone graft that improves the overall quality of care in orthopedic and spinal procedures. This benefit was further demonstrated with recent level 1 clinical data in which MagnetOs outperformed the gold standard autograft by 73% in posterior spinal fusion in a difficult-to-treat real life patient population, of which 20% were current smokers.
공시 • Nov 29Kuros Biosciences Receives FDA Clearance for Use of Magnetos in Interbody Spinal CagesKuros Biosciences announced that MagnetOs Flex Matrix has been cleared for use in the interbody space by the U.S. Food and Drug Administration (FDA). As a result, it can now be used in any interbody space (cervical, thoracic, lumbar); and in any cage approved for use with a bone void filler. With interbody cages being used in almost half of the estimated 1.5 million instrumented spinal fusion procedures conducted annually in the USA, this news is especially significant for surgeons. MagnetOs Flex Matrix is uniquely well suited to interbody applications. Due to its excellent granule retention, it stays strong yet flexible even when wet - for easy placement either through a funnel or packed directly into any cage, of any size. MagnetOs Flex Matrix is the first Kuros product to receive interbody clearance, having already been cleared by the FDA for use in posterolateral fusions. Due to its unique fibrillar and flexible structure, this open matrix bone graft promotes bone growth even in soft tissue by optimizing the effect of Kuros' established NeedleGrip surface technology.